RU2018109426A - Химерные антигенные рецепторы со встроенными контролируемыми функциями - Google Patents

Химерные антигенные рецепторы со встроенными контролируемыми функциями Download PDF

Info

Publication number
RU2018109426A
RU2018109426A RU2018109426A RU2018109426A RU2018109426A RU 2018109426 A RU2018109426 A RU 2018109426A RU 2018109426 A RU2018109426 A RU 2018109426A RU 2018109426 A RU2018109426 A RU 2018109426A RU 2018109426 A RU2018109426 A RU 2018109426A
Authority
RU
Russia
Prior art keywords
seq
sequence
paragraphs
binding domain
chimeric antigenic
Prior art date
Application number
RU2018109426A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109426A3 (enExample
Inventor
Александр ДЖИЛЛЕРАТ
Филипп ДЮШАТО
Лорен ПУАРО
Original Assignee
Селлектис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлектис filed Critical Селлектис
Publication of RU2018109426A publication Critical patent/RU2018109426A/ru
Publication of RU2018109426A3 publication Critical patent/RU2018109426A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018109426A 2015-08-24 2016-08-24 Химерные антигенные рецепторы со встроенными контролируемыми функциями RU2018109426A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570545 2015-08-24
DKPA201570545 2015-08-24
EP15202592 2015-12-23
EP15202592.0 2015-12-23
PCT/EP2016/069918 WO2017032777A1 (en) 2015-08-24 2016-08-24 Chimeric antigen receptors with integrated controllable functions

Publications (2)

Publication Number Publication Date
RU2018109426A true RU2018109426A (ru) 2019-09-26
RU2018109426A3 RU2018109426A3 (enExample) 2020-02-28

Family

ID=56842804

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018109426A RU2018109426A (ru) 2015-08-24 2016-08-24 Химерные антигенные рецепторы со встроенными контролируемыми функциями

Country Status (12)

Country Link
US (1) US10988542B2 (enExample)
EP (1) EP3341410B1 (enExample)
JP (1) JP6894430B2 (enExample)
KR (1) KR20180042361A (enExample)
CN (1) CN107922498A (enExample)
AU (1) AU2016313082B2 (enExample)
BR (1) BR112018002189A2 (enExample)
CA (1) CA2995632C (enExample)
IL (1) IL257138A (enExample)
MX (1) MX2018001533A (enExample)
RU (1) RU2018109426A (enExample)
WO (1) WO2017032777A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018169948A1 (en) 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JOP20180027A1 (ar) * 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CA3063719A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
CN107312797B (zh) * 2017-07-28 2021-06-18 广州中科蓝华生物科技有限公司 一种蛋白调控系统及其制备方法和应用
CA3076337A1 (en) 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
EP3723787A4 (en) * 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
RU2020122708A (ru) * 2017-12-14 2022-01-14 2севэнти био, Инк. Рецепторы nkg2d daric
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
KR20200101942A (ko) 2017-12-20 2020-08-28 세인트 안나 킨더크렙스포르슝 리간드 조절 단백질-단백질 상호작용 시스템
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3757133A4 (en) 2018-02-11 2021-12-01 Jiangsu Hengrui Medicine Co., Ltd. ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20210228629A1 (en) * 2018-04-27 2021-07-29 Crispr Therapeutics Ag Anti-bcma car-t-cells for plasma cell depletion
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
MX2021003435A (es) 2018-09-28 2021-06-15 Massachusetts Inst Technology Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
US20220267435A1 (en) * 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
JP2022512594A (ja) * 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体（ｃａｒ）の群
CN113366479A (zh) 2018-12-14 2021-09-07 蓝鸟生物公司 二聚化剂调节的免疫受体复合物
BR112021013173A2 (pt) * 2019-01-04 2021-09-28 The University Of Chicago Sistemas e métodos para modular rna
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20220004750A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. Cd33 결합 폴리펩타이드 및 이의 용도
BR112021020999A2 (pt) 2019-05-04 2021-12-14 Inhibrx Inc Polipeptídeos de ligação à clec12a e usos dos mesmos
AU2020269268A1 (en) 2019-05-04 2021-11-11 Inhibrx Biosciences, Inc. CD123-binding polypeptides and uses thereof
CA3139512A1 (en) * 2019-05-08 2020-11-12 Inhibrx, Inc. Cd123 targeted immunotherapies
EP3966251A4 (en) * 2019-05-08 2023-05-10 Inhibrx, Inc. IMMUNOTHERAPIES TARGETED AGAINST CD33
EP3966249A4 (en) * 2019-05-08 2023-05-10 2seventy bio, Inc. IMMUNOTHERAPIES TARGETED AGAINST CLL-1
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
JP2022551820A (ja) * 2019-10-15 2022-12-14 エフ．ホフマン－ラ ロシュ アーゲー 細胞内または小胞内生体分子相互作用を検出するための人工膜貫通タンパク質
WO2021087183A1 (en) * 2019-10-31 2021-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
EP4168438A4 (en) * 2020-06-22 2024-07-10 Ramot at Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
CN120112309A (zh) * 2022-09-20 2025-06-06 丹娜-法伯癌症研究院 受体介导的胞吞作用用于治疗剂的靶向降解和递送
CN119638840A (zh) * 2023-09-15 2025-03-18 东莞市朋志生物科技有限公司 一种抗糖类抗原153的抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
EP3119425B1 (en) 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor

Also Published As

Publication number Publication date
KR20180042361A (ko) 2018-04-25
EP3341410A1 (en) 2018-07-04
AU2016313082B2 (en) 2022-03-31
BR112018002189A2 (pt) 2018-09-18
MX2018001533A (es) 2018-03-15
WO2017032777A1 (en) 2017-03-02
EP3341410B1 (en) 2021-06-02
US10988542B2 (en) 2021-04-27
CN107922498A (zh) 2018-04-17
IL257138A (en) 2018-03-29
CA2995632A1 (en) 2017-03-02
AU2016313082A1 (en) 2018-02-15
JP6894430B2 (ja) 2021-06-30
US20180237533A1 (en) 2018-08-23
CA2995632C (en) 2023-02-07
JP2018525006A (ja) 2018-09-06
RU2018109426A3 (enExample) 2020-02-28

Similar Documents

Publication Publication Date Title
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
JP2018525006A5 (enExample)
US20230025506A1 (en) Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
IL277398B2 (en) Pd-l1 binding affimers, and uses related thereto
CN107428830B (zh) 单体fc结构域
JP2022109915A (ja) Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2020517295A5 (enExample)
AU2015370679C1 (en) Cell
JP2020529970A5 (enExample)
JP7282760B2 (ja) バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
CN110088126A (zh) Icos配体变体免疫调节蛋白及其用途
US20180021418A1 (en) Engineered t cells and uses therefor
JP2019068822A5 (enExample)
EP3606946A1 (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
JP7749319B2 (ja) Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
EP3491013A1 (en) Cd155 variant immunomodulatory proteins and uses thereof
EP3432924A1 (en) Cell secreted minibodies and uses thereof
RS64870B1 (sr) Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe
JP2020513754A5 (enExample)
CA2984484A1 (en) Compositions and methods of chimeric autoantibody receptor t cells
RU2020109577A (ru) Клетка
KR20210135987A (ko) Cd86 변이체 면역조절 단백질 및 그의 용도
KR102371151B1 (ko) 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
NO313883B1 (no) Löselig fusjonsmolekyl og rekombinant fusjonsmolekyl som har bindingsspesifisitet for CD11a/CD18

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200914